ROSEN, A TOP RANKED LAW FIRM, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – VTYX
April 08, 2024 16:48 ET
|
The Rosen Law Firm PA
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ventyx Biosciences, Inc. (NASDAQ: VTYX): (i) pursuant...
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
April 01, 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 Inhibitor for the Treatment of Plaque Psoriasis, at AAD Annual Meeting
March 09, 2024 12:00 ET
|
Alumis Inc
Alumis today announced the presentation of positive clinical data from a Phase 2 clinical trial of ESK-001 at AAD 2024.
STRATA Skin Sciences Announces Initiative to Expand Treatment Coverage
March 07, 2024 08:00 ET
|
STRATA Skin Sciences, Inc.
HORSHAM, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and...
Alumis Announces Upsized $259M Series C Financing to Advance Clinical-stage Pipeline of Oral Therapies Designed to Address Immune Dysfunction
March 06, 2024 08:00 ET
|
Alumis Inc
– Financing led by Foresite Capital, Samsara BioCapital and venBio Partners with participation from additional new and existing investors – – Proceeds will support ongoing comprehensive mid to...
Alumis Announces Late-Breaker Psoriasis Phase 2 Data Presentation for Allosteric TYK2 Inhibitor ESK-001 at the American Academy of Dermatology 2024 Annual Meeting
March 04, 2024 09:00 ET
|
Alumis Inc
– Late-breaking oral presentation to highlight efficacy and safety of ESK-001 in a Phase 2 clinical trial and open label extension (OLE) study in adults with moderate-to-severe plaque psoriasis...
Mindera Health™ Launches Program with Innovative Pharmacy Benefit Manager to Improve Management of Moderate-to-Severe Psoriasis Patients Through Precision Medicine
February 29, 2024 09:00 ET
|
Mindera Health
San Diego, CA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Mindera Health, developer of Mind.Px™, the first realization of precision medicine in psoriasis, has formed a partnership with Liviniti™, an...
Dermatitis Global Market Report 2024: Analysis Reveals Key Trends in Biologics and Personalized Medicine Approaches - Long-term Forecasts to 2028 and 2033
January 26, 2024 03:32 ET
|
Research and Markets
Dublin, Jan. 26, 2024 (GLOBE NEWSWIRE) -- The "Dermatitis Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. There is significant growth underway in the global...
Psoriasis Global Market Report 2024: Market to Surge to $39.17 Billion by 2028, Middle East Poised for Rapid Growth - Long-term Forecasts to 2033
January 26, 2024 03:17 ET
|
Research and Markets
Dublin, Jan. 26, 2024 (GLOBE NEWSWIRE) -- The "Psoriasis Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The psoriasis market is undergoing significant...
BMS Attributes Sotyktu Falling Short of Growth Expectations to Access, but Recent Spherix Global Insights’ Data Suggest Safety Concerns Are More of a Barrier to Increased Uptake
December 07, 2023 12:01 ET
|
Spherix Global Insights
Exton, PA, Dec. 07, 2023 (GLOBE NEWSWIRE) -- While access took the forefront of BMS’ response to Sotyktu (deucravacitinib) not meeting growth expectations during the company’s Q3 earnings call,...